Dose Insider / Glossary / Amylin

AmylinWhat it is, what it does and which medicines copy it

Updated November 20, 2026 · 3 min read · SYMLIN label, Walker 2025, Volčanšek 2025, Enebo 2021

Amylin is a hormone made by the same cells in the pancreas that make insulin, and released together with it after a meal. It helps end a meal by promoting fullness, slows the emptying of the stomach and holds back glucagon.

10.8%Cagrilintide 4.5 mg, weight lost by week 26
Weight lost by week 26Cagrilintide alone, phase 2 trial, % of weightCagrilintide 4.5 mg10.8%Liraglutide 3 mg9.0%Placebo3.0%Weight lost by week 26Cagrilintide alone, phase 2 trial, % of weightCagrilintide 4.5 mg10.8%Liraglutide 3 mg9.0%Placebo3.0%

An amylin analog on its own did slightly better than liraglutide at the doses tested.

On this page

Medicines that copy it are called amylin analogs: pramlintide, sold as Symlin since 2005, and cagrilintide, an experimental weekly injection that is half of the combination CagriSema.1,2,3

What amylin does

The Symlin label describes amylin as stored with insulin in the beta cells of the pancreas and released with it in response to food, so that the two rise and fall together in healthy people. People with type 1 and type 2 diabetes release less of both after meals.1 The label lists three effects, based on nonclinical studies:1

A 2025 review by Špela Volčanšek and colleagues calls amylin an anorexic hormone, one that reduces appetite, and adds that it may increase energy expenditure.3 Those effects overlap with what GLP-1 does, which is why the two have been combined.

Pramlintide, the first amylin medicine

Pramlintide, sold as Symlin, was approved in 2005. It is not a weight medicine: it is approved as an add-on for people with type 1 or type 2 diabetes who use mealtime insulin and have not reached their target despite optimal insulin treatment.1 It carries a boxed warning: used with insulin it raises the risk of severe low blood sugar, particularly in type 1 diabetes, usually within 3 hours of an injection.1

A 2025 review by Christopher Walker and colleagues notes that pramlintide was also explored for obesity. Efforts to build an amylin-based weight medicine then stalled over how often it had to be injected, safety and formulation, until advances in peptide chemistry revived the field.2 The Volčanšek review names the hurdles more precisely: complex receptor biology, the limits of animal models, the tendency of human amylin to form amyloid clumps, and its short time in the body.3

Cagrilintide, the long-acting analog

Cagrilintide is a long-acting amylin analog from Novo Nordisk, injected once a week. In a 26-week dose-finding trial of it alone, published in 2021, weight fell by 6.0% to 10.8% across doses from 0.3 mg to 4.5 mg, against 3.0% on placebo. At 4.5 mg it did a little better than liraglutide 3 mg, 10.8% against 9.0%.4 Combined with semaglutide 2.4 mg as CagriSema, it lowered weight by 20.4% over 68 weeks in adults without diabetes, against 3.0% on placebo.5 In adults with type 2 diabetes the same combination lowered weight by 13.7%, against 3.4%.6

Side effects

Because amylin slows the stomach, its medicines share the stomach complaints of the GLP-1 class. In the cagrilintide trial, stomach and gut events affected 41% to 63% on the drug against 32% on placebo, mainly nausea, reported by 20% to 47% against 18%.4 In REDEFINE 1, where cagrilintide was combined with semaglutide, such events affected 79.6% on the combination against 39.9% on placebo, and were mainly short-lived and mild to moderate.5 Our page on nausea on a GLP-1 covers what helps.

Why the interest now

The Walker review points to two concerns with GLP-1-based medicines that drive the search for alternatives. One is the loss of lean body mass along with fat. The other is the growing use of weight medicines in people without other conditions, which it says needs further regulatory and ethical thought.2 Whether amylin analogs protect lean mass better is still being studied.

Sources

  1. SYMLINPEN (pramlintide acetate) injection prescribing information. AstraZeneca; DailyMed, U.S. National Library of Medicine, version published August 20, 2024; boxed warning and sections 1 and 12.1. dailymed.nlm.nih.gov
  2. Walker CS, Aitken JF, Vazhoor Amarsingh G, Zhang S, Cooper GJS. Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus. Nat Rev Endocrinol 2025;21:482-494. doi:10.1038/s41574-025-01125-9
  3. Volčanšek Š, Koceva A, Jensterle M, Janež A, Muzurović E. Amylin: from mode of action to future clinical potential in diabetes and obesity. Diabetes Ther 2025;16:1207-1227. doi:10.1007/s13300-025-01733-8
  4. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021;398:2160-2172. Funded by Novo Nordisk. doi:10.1016/S0140-6736(21)01751-7
  5. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med 2025;393:635-647. Funded by Novo Nordisk. doi:10.1056/NEJMoa2502081
  6. Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). N Engl J Med 2025;393:648-659. Funded by Novo Nordisk. doi:10.1056/NEJMoa2502082

Related analyses

Log meals, doses and fullness, and see how your appetite changes.

Open Dose Insider